{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:08:50Z","timestamp":1786118930678,"version":"build-2736575974"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,7]]},"DOI":"10.1097\/cad.0b013e32830138f9","type":"journal-article","created":{"date-parts":[[2008,5,22]],"date-time":"2008-05-22T03:04:54Z","timestamp":1211425494000},"page":"607-612","source":"Crossref","is-referenced-by-count":17,"title":["Decrease of CD117 expression as possible prognostic marker for recurrence in the resected specimen after imatinib treatment in patients with initially unresectable gastrointestinal stromal tumors: a clinicopathological analysis"],"prefix":"10.1097","volume":"19","author":[{"given":"Amir","family":"Mearadji","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"den Bakker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albertus N.","family":"van Geel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander M.M.","family":"Eggermont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Sleijfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaap","family":"Verweij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes H.W.","family":"de Wilt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelis","family":"Verhoef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-7-20210203","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1136\/jcp.54.2.96","article-title":"The histopathological differential diagnosis of gastrointestinal stromal tumours","volume":"54","author":"Graadt van Roggen","year":"2001","journal-title":"J Clin Pathol"},{"key":"R2-7-20210203","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1053\/hupa.2002.123545","article-title":"Diagnosis of gastrointestinal stromal tumors: a consensus approach","volume":"33","author":"Fletcher","year":"2002","journal-title":"Hum Pathol"},{"key":"R3-7-20210203","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1080\/00016470410001708340","article-title":"Gastrointestinal stromal tumors: a review","volume":"75","author":"Joensuu","year":"2004","journal-title":"Acta Orthop Scand Suppl"},{"key":"R4-7-20210203","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1053\/hupa.2002.124123","article-title":"Evaluation of malignancy and prognosis of gastrointestinal stromal tumors: a review","volume":"33","author":"Miettinen","year":"2002","journal-title":"Human Pathol"},{"key":"R5-7-20210203","first-page":"728","article-title":"CD 117: a sensitive marker for gastrointestinal stromal tumors that is more specific than CD34","volume":"11","author":"Sarloma-Rikal","year":"1998","journal-title":"Mod Pathol"},{"key":"R6-7-20210203","first-page":"1259","article-title":"Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal","volume":"152","author":"Kindblom","year":"1998","journal-title":"Am J Pathol"},{"key":"R7-7-20210203","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/S0140-6736(04)17098-0","article-title":"Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial","volume":"364","author":"Verweij","year":"2004","journal-title":"Lancet"},{"key":"R8-7-20210203","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1056\/NEJMoa020461","article-title":"Efficacy and safety of imatinib mesylate in advanced gastrointestinal stroma tumors","volume":"347","author":"Demetri","year":"2002","journal-title":"N Engl J Med"},{"key":"R9-7-20210203","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1097\/01.sla.0000236630.93587.59","article-title":"Results of tyrosine kinase therapy followed by surgical resection for metastatic gastrointestinal stromal tumor","volume":"245","author":"DeMatteo","year":"2007","journal-title":"Ann Surg"},{"key":"R10-7-20210203","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1097\/01.sla.0000242710.36384.1b","article-title":"Surgery of residual disease following molecular-targeted therapy with imatinib mesylate in advanced\/metastatic GIST","volume":"245","author":"Gronchi","year":"2007","journal-title":"Ann Surg"},{"key":"R11-7-20210203","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1158\/1078-0432.CCR-06-1508","article-title":"Pathologic and molecular heterogeneity in imatinib-stable or imatinib-responsive gastrointestinal stromal tumors","volume":"13","author":"Agaram","year":"2007","journal-title":"Clin Cancer Res"},{"key":"R12-7-20210203","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1245\/s10434-006-9228-0","article-title":"Surgical management after neoadjuvant imatinib therapy in gastrointestinal stromal tumours (GISTs) with respect to imatinib resistance caused by secondary KIT mutations","volume":"14","author":"Haller","year":"2006","journal-title":"Ann Surg Oncol"},{"key":"R13-7-20210203","doi-asserted-by":"crossref","first-page":"4182","DOI":"10.1158\/1078-0432.CCR-04-2245","article-title":"Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation","volume":"11","author":"Antonescu","year":"2005","journal-title":"Clin Cancer Res"},{"key":"R14-7-20210203","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1016\/j.ejca.2005.04.005","article-title":"RECIST versus WHO: prospective comparison of response criteria in an EORTC phase II clinical trial investigating ET-743 in advanced soft tissue sarcoma","volume":"41","author":"Therasse","year":"2205","journal-title":"Eur J Cancer"},{"key":"R15-7-20210203","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s101200300005","article-title":"Clinicopathologic study of primary malignant gastrointestinal stromal tumor of the stomach, with special reference to prognostic factors: analysis of results in 140 surgically resected patients","volume":"6","author":"Fujimoti","year":"2003","journal-title":"Gastric Cancer"},{"key":"R16-7-20210203","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1016\/S0959-8049(02)80601-3","article-title":"Clinical presentation of gastrointestinal stromal tumors and treatment of operable disease","volume":"38","author":"Roberts","year":"2002","journal-title":"Eur J Cancer"},{"key":"R17-7-20210203","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.ejso.2005.11.021","article-title":"An audit of surgical management of gastrointestinal stromal tumours (GIST)","volume":"32","author":"Bucher","year":"2006","journal-title":"Eur J Surg Oncol"},{"key":"R18-7-20210203","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1634\/theoncologist.11-1-9","article-title":"Management of gastrointestinal stromal tumours in the imatinib era: selected case studies","volume":"11","author":"Benjamin","year":"2006","journal-title":"Oncologist"},{"key":"R19-7-20210203","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1245\/s10434-006-9034-8","article-title":"Surgical resection of gastrointestinal stromal tumors after treatment with imatinib","volume":"14","author":"Andtbacka","year":"2007","journal-title":"Ann Surg Oncol"},{"key":"R20-7-20210203","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1245\/s10434-006-9047-3","article-title":"Impact of surgery on advanced gastrointestinal stromal tumors (GIST) in the imatinib era","volume":"13","author":"Bonvalot","year":"2006","journal-title":"Ann Surg Oncol"},{"key":"R21-7-20210203","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1200\/JCO.2005.05.3439","article-title":"Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors","volume":"24","author":"Raut","year":"2006","journal-title":"J Clin Oncol"},{"key":"R22-7-20210203","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/jso.20466","article-title":"Surgical treatment of patients with initially inoperable and\/or metastatic gastrointestinal stromal tumors (GIST) during therapy with imatinib mesylate","volume":"93","author":"Rutkowski","year":"2006","journal-title":"J Surg Oncol"},{"key":"R23-7-20210203","doi-asserted-by":"crossref","first-page":"5795","DOI":"10.1200\/JCO.2005.11.601","article-title":"Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group study","volume":"23","author":"van Glabbeke","year":"2005","journal-title":"J Clin Oncol"},{"key":"R24-7-20210203","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s11864-001-0070-0","article-title":"Gastrointestinal stromal tumors","volume":"2","author":"Blanke","year":"2001","journal-title":"Curr Treat Options Oncol"},{"key":"R25-7-20210203","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1200\/JCO.2006.09.0183","article-title":"Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group","volume":"25","author":"Blay","year":"2007","journal-title":"J Cin Oncol"},{"key":"R26-7-20210203","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1097\/00000478-200604000-00008","article-title":"Gastrointestinal stromal tumors of the jejunum and ileum: a clinicopathologic, immunohistochemical, and molecular genetic study of 906 cases before imatinib with long-term follow-up","volume":"30","author":"Miettinen","year":"2006","journal-title":"Am J Surg Pathol"}],"container-title":["Anti-Cancer Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/CAD.0b013e32830138f9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T17:05:08Z","timestamp":1786035908000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00001813-200807000-00007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,7]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.1097\/cad.0b013e32830138f9","relation":{},"ISSN":["0959-4973"],"issn-type":[{"value":"0959-4973","type":"print"}],"subject":[],"published":{"date-parts":[[2008,7]]}}}